SCHEDULE 13G/A 0000902664-25-002357 0001784547 XXXXXXXX LIVE 1 Voting Common Stock, par value $0.0001 per share 06/30/2025 0001799448 Aligos Therapeutics, Inc. 01626L204 ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 Rule 13d-1(b) Woodline Partners LP DE 518300.00 0.00 518300.00 0.00 518300.00 N 9.8 IA PN Aligos Therapeutics, Inc. One Corporate Drive, 2nd Flood, South San Francisco, CA, 94080. This statement is filed by Woodline Partners LP ("Woodline Partners" or the "Reporting Person"), a Delaware limited partnership, and the investment adviser to Woodline Master Fund LP (the "Woodline Fund"), with respect to the shares of voting common stock, par value $0.0001 per share ("Voting Common Stock") of Aligos Therapeutics, Inc. (the "Company") directly held by the Woodline Fund. The filing of this statement should not be construed as an admission that the foregoing persons or the Reporting Person is, for the purposes of the Act, the beneficial owner of the shares of Voting Common Stock reported herein. The address of the business office of Woodline Partners is 4 Embarcadero Center, Suite 3450, San Francisco, CA 94111. Woodline Partners is a Delaware limited partnership. N IA The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 5,314,801 shares of Voting Common Stock outstanding as of May 1, 2025, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the Securities and Exchange Commission on May 6, 2025. 9.8% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference. Y N See Item 2(a). Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Woodline Partners LP /s/ Erin Mullen 08/14/2025